June 17, 2009 - Sanford Children’s Hospital is the first children’s facility in the U.S. to offer new CT technology to patients that significantly reduces a child’s radiation exposure during a CT scan.

June 17, 2009 – Molecular Insight Pharmaceuticals Inc. presented clinical data on a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 2009 annual meeting of the Society of Nuclear Medicine (SNM) in Toronto.


June 16, 2009 - “Our profession faces one of the most significant crises in its history,” said Michael Graham, M.D., the new president of the Society of Nuclear Medicine (SNM), as he addressed a room packed with national and international press, hungry for accountability and solutions to the shortage of nuclear medicine radioisotopes.

June 16, 2009 - While the healthcare community awaited the first "Meaningful Use" definition due today, healthcare stakeholders struggled to define one of the key medical terms for the ARRA.

June 16, 2009 – The study "Does Positron Emission Tomography Imaging in the Surgical Treatment of Colorectal Liver Metastases add any Value?" by Bastiaan Wiering, M.D., won Siemens Award for Excellence in Practice-Based Research at SNM’s 56th Annual Meeting in Toronto.

June 16, 2009 - In testimony before the Listening Panel of the Federal Coordinating Council for Comparative Effectiveness Research (FCCC) on June 10, 2009, ECRI Institute President and Chief Executive Officer Jeffrey C.

June 16, 2009 – Dilon Technologies Inc. today announced the release of a new Dilon 6800 Software update, including enhancements for both breast and general nuclear medicine applications image processing.

June 16, 2009 - Michael Reitermann will become the new CEO of Siemens Healthcare, U.S. organization, responsible for sales, marketing, service and logistics across the Siemens Healthcare portfolio, including medical imaigng equipment, healthcare information technology and medical therapy effective July 1, 2009.

June 12, 2009 – Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer's disease compared to healthy volunteers.

June 16, 2009 – MILabs introduced at the Annual SNM meeting its novel U-SPECT/CT system, a Micro-SPECT system that is fully integrated with the MILabs high-throughput, low dose U-CT. The company also announced it has already contracted to install two U-SPECT/CT systems.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now